![All lanes : Anti-Rad9 antibody [7B11] (ab117848) at 1/2000 dilutionLane 1 : HepG2 lysateLane 2 : HeLa lysateLane 3 : HT29 lysateLane 4 : A549 lysateLane 5 : COS7 lysateLane 6 : Jurkat lysateLane 7 : MDCK lysateLane 8 : PC12 lysateLane 9 : MCF7 lysateLysates/proteins at 35 µg per lane.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_4/20196_Rad9-Primary-antibodies-ab117848-4.jpg)
All lanes : Anti-Rad9 antibody [7B11] (ab117848) at 1/2000 dilutionLane 1 : HepG2 lysateLane 2 : HeLa lysateLane 3 : HT29 lysateLane 4 : A549 lysateLane 5 : COS7 lysateLane 6 : Jurkat lysateLane 7 : MDCK lysateLane 8 : PC12 lysateLane 9 : MCF7 lysateLysates/proteins at 35 µg per lane.

ab117848, at a 1/50 dilution, staining Human Rad9 in breast adenocarcinoma, using Immunohistochemistry, formalin/PFA-fixed paraffin embedded tissue.

ab117848, at a 1/50 dilution, staining Human Rad9 in colon, using Immunohistochemistry, formalin/PFA-fixed paraffin embedded tissue.

ab117848, at a 1/50 dilution, staining Human Rad9 in colon adenocarcinoma, using Immunohistochemistry, formalin/PFA-fixed paraffin embedded tissue.

ab117848, at a 1/50 dilution, staining Human Rad9 in lung carcinoma, using Immunohistochemistry, formalin/PFA-fixed paraffin embedded tissue.

ab117848, at a 1/50 dilution, staining Human Rad9 in pancreas carcinoma, using Immunohistochemistry, formalin/PFA-fixed paraffin embedded tissue.